Etoposide Capsules Rx
Generic Name and Formulations:
Etoposide 50mg; contain parabens.
Various generic manufacturers
Indications for Etoposide Capsules:
Small cell lung cancer.
Round dose to nearest 50mg increment. Range: 70mg/m2 per day for 4 days to 100mg/m2 per day for 5 days. Repeat course every 3 to 4 weeks after recovery (esp myelosuppression). Renal impairment (CrCl ≤50mL/min): reduce dose (see literature). Consider dose reduction with existing myelosuppression due to previous radiation or chemotherapy.
Monitor blood (esp CBC/differential, platelets, hemoglobin) before each cycle and during therapy; renal function. Withhold dose if platelet count <50,000/mm3 or ANC <500/mm3. Hypoalbuminemia. Elderly. Pregnancy (Cat.D); nursing mothers: not recommended.
Potentiated by cyclosporine. Additive toxicity with radiation, other cytotoxic therapies.
GI upset, mucositis, myelosuppression (esp. neutropenia, thrombocytopenia; may be fatal), alopecia, fever, infections, peripheral neurotoxicity; hypersensitivity reactions, acute leukemia (rare); others.
Formerly known under the brand name VePesid.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Predictors of Weight Loss in Postpartum Women With Gestational Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D